Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Wakely PE, Siddiqui MT. Fine-needle aspiration cytopathology of soft tissue myoepithelioma: an analysis of seven cases. J Am Soc Cytopathol. 2022;11(1):31-39.

Young A, Bu W, Jiang W, Ku A, Kapali J, Dhamne S, et al. Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer. Cancer Prev Res (Phila). 2022;15(1):3-10.

McLean-Holden AC, Rooper LM, Lubin DJ, Magliocca KR, Manucha V, Sadow PM, et al. Frankly Invasive Carcinoma Ex-intraductal Carcinoma: Expanding on an Emerging and Perplexing Concept in Salivary Gland Tumor Pathology. Head Neck Pathol. 2022;16(3):657-669.

Leeman-Neill RJ, Soderquist CR, Montanari F, Raciti P, Park D, Radeski D, et al. Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. Haematologica. 2022;107(1):201-210.

Gerber N, Vella A, Racine-Brzostek S, Platt SL. Rapid Absolute Neutrophil Count Testing Guides Targeted Antimicrobial Therapy in Febrile Pediatric Oncology Patients. Pediatr Emerg Care. 2022;38(2):e743-e745.

Tow CY, Castrodad-Rodríguez CA, Panarelli N, Massoumi H. Finding Nivo: A Case Report of 2 Forms of Nivolumab-Induced Liver Injury in an Allograft Liver in the Immediate Post-Transplant Period. Transplant Proc. 2022;54(10):2794-2796.

Tang F, Xu D, Wang S, Wong CK, Martinez-Fundichely A, Lee CJ, et al. Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science. 2022;376(6596):eabe1505.

Magro CM, Mo JH, Kerns MJ. Leukocytoclastic vasculitis in association with linear epidermal basement membrane zone immunoglobulin deposition: Linear vasculitis. Clin Dermatol. 2022;40(6):639-650.

Kudalkar EM, Pang C, Haag MM, Pollyea DA, Kamdar M, Xu G, et al. 21q22 amplification detection in three patients with acute myeloid leukemia: cytogenomic profiling and literature review. Mol Cytogenet. 2022;15(1):30.

Fangusaro JR, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman NI, et al. Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study. Neuro Oncol. 2022;24(8):1404.